Patents by Inventor Shoshana Eitan

Shoshana Eitan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NALOXONE NANOPARTICLE COMPOSITIONS AND METHODS THEREOF
    Publication number: 20230201369
    Abstract: The present disclosure provides nanoparticle compositions comprising i) a polymeric nanoparticle, ii) one or more ligands conjugated to the polymeric nanoparticle, and iii) naloxone. The disclosure also provides methods and pharmaceutical compositions comprising the nanoparticle compositions for use in treating patients with various disease states.
    Type: Application
    Filed: April 29, 2021
    Publication date: June 29, 2023
    Inventors: Shoshana EITAN, Naga Venkata Ravi Kumar MAJETI
  • Enzymatically-produced oligodendrocyte cytotoxic dimeric IL-2 factor
    Patent number: 5962404
    Abstract: An enzymatically-producible dimeric IL-2 such as mammalian, more particularly, human dimeric IL-2, having oligodendrocyte cytotoxic activity, is useful as active ingredient of pharmaceutical compositions for inducing and facilitating regeneration of injured nerves of the central nervous system in mammals, including humans.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: October 5, 1999
    Assignee: Yeda Research & Development Co., Ltd.
    Inventors: Michal Eisenbach-Schwartz, Shoshana Eitan
  • Nerve-derived transglutaminase enzyme
    Patent number: 5840295
    Abstract: The invention provides a new nerve-derived transglutaminase enzyme that converts immune-derived IL-2 to dimeric IL-2 having oligodendrocyte cytotoxic activity. Both the nerve-derived transglutaminase and the dimeric mammalian, e.g. human, IL-2, are for use as active ingredients in pharmaceutical compositions for inducing and facilitating regeneration of injured nerves of the central nervous system in mammals.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 24, 1998
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Michal Schwartz, Shoshana Eitan
  • Enzymatically-produced dimeric IL-2 and a nerve-derived transglutaminase enzyme for its preparation
    Patent number: 5514565
    Abstract: The invention provides a new nerve-derived transglutaminase enzyme that converts immune-derived IL-2 to dimeric IL-2 having oligodendrocyte cytotoxic activity. Both the nerve-derived transglutaminase and the dimeric mammalian, e.g. human, IL-2, are for use as active ingredients in pharmaceutical compositions for inducing and facilitating regeneration of injured nerves of the central nervous system in mammals.
    Type: Grant
    Filed: July 30, 1993
    Date of Patent: May 7, 1996
    Assignee: Yeda Research & Development Co. Ltd.
    Inventors: Michael Schwartz, Shoshana Eitan